“After detailed deliberation, the committee recommended that the SII should submit the following data/information for updated safety data of Phase II/III clinical trial in the country, immunogenicity data from the clinical trial in UK and India and the outcome of the assessment of UK MHRA for grant of EUA,” DCGI stated.
Covishield is the COVID-19 vaccine candidate created by AstraZeneca in collaboration with Oxford University, and is at present becoming tested and created by the SII in India
The vaccine has shown 70% efficacy in its interim evaluation and Poonawalla had earlier stated that the shot is most likely to be prepared by the finish of December this year.